Content Type: Policy Interactions

Testimony: Addressing Pharmaceutical Patent Abuses Could Lower Drug Spending and Improve Patient Outcomes

April 8, 2026

Identifying Therapeutic Alternatives for State PDAB Affordability Reviews

April 8, 2026

Determining Upper Payment Limits: Considerations for State PDABs

April 8, 2026

Health Technology Assessment in Prescription Drug Coverage and Pricing Decisions: Examples From Other Countries

April 8, 2026

Testimony: Under the Influence: Can We Provide Doctors an Alternative to Biased Drug Reviews?

April 8, 2026

Prescription Drug Price Measures to Inform State Upper Payment Limits

April 8, 2026

Testimony: Why Are Some Generic Drugs Skyrocketing in Price?

April 8, 2026

Testimony in Support of H.866: an Act Relating to Prescription Drug Manufacturer Cost Transparency

April 8, 2026

Testimony on the Impact of S.1048: A Bill to Improve Transparency of Drug Research and Development Costs

April 8, 2026

Testimony in Support of Legislation on Pharmaceutical Transparency and Price Gouging

April 8, 2026

Testimony on the Impact of S.706/H. 1333: An Act to Ensure Prescription Drug Cost Transparency and Affordability

April 8, 2026

Testimony: High Drug Prices in the US: What We Can Learn From Other Countries and Some US States

April 8, 2026